LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,149
تعداد مقالات10,519
تعداد مشاهده مقاله45,426,780
تعداد دریافت فایل اصل مقاله11,296,860
Abbasi, Samaneh, Khademi, Sara, Montazerabadi, Alireza, Sahebkar, Amirhossein. (1403). FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review. سامانه مدیریت نشریات علمی, 14(4), 323-334. doi: 10.31661/jbpe.v0i0.2404-1754
Samaneh Abbasi; Sara Khademi; Alireza Montazerabadi; Amirhossein Sahebkar. "FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review". سامانه مدیریت نشریات علمی, 14, 4, 1403, 323-334. doi: 10.31661/jbpe.v0i0.2404-1754
Abbasi, Samaneh, Khademi, Sara, Montazerabadi, Alireza, Sahebkar, Amirhossein. (1403). 'FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review', سامانه مدیریت نشریات علمی, 14(4), pp. 323-334. doi: 10.31661/jbpe.v0i0.2404-1754
Abbasi, Samaneh, Khademi, Sara, Montazerabadi, Alireza, Sahebkar, Amirhossein. FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review. سامانه مدیریت نشریات علمی, 1403; 14(4): 323-334. doi: 10.31661/jbpe.v0i0.2404-1754

FAP-Targeted Nanoparticle-based Imaging in Cancer: A Systematic Review

Journal of Biomedical Physics and Engineering
دوره 14، شماره 4، آبان 2024، صفحه 323-334    اصل مقاله (1 M)
نوع مقاله: Systematic Review
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.2404-1754
نویسندگان
Samaneh Abbasi1؛ Sara Khademi2؛ Alireza Montazerabadi* 1، 3؛ Amirhossein Sahebkar* 4، 5، 6
1Department of Medical Physics, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of Radiology Technology, School of Paramedical Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
3Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
5Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
6Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
چکیده
Background: Fibroblast Activation Protein (FAP)-targeted nanoparticles (NPs) are designed to accumulate in cancerous stroma. These NPs hold promise for imaging applications in cancer therapy.
Objective: This systematic review aimed to comprehensively explore the use of FAP-targeting NPs for cancer diagnosis through different imaging modalities.
Material and Methods: This systematic review followed the framework proposed by O’Malley and Arksey. Peer-reviewed studies were searched in the Scopus, Science Direct, PubMed, and Google Scholar databases. Eligible studies were selected, and data were extracted to investigate the FAP-targeting NPs in imaging. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline was also utilized to present the results.
Results: Five studies met the specified inclusion criteria and were finally selected for analysis. The extracted data was classified into two categories: general and specific data. The general group indicated that most studies have been conducted in Mexico and have increased since 2022, and the specific group showed that colorectal cancer and Nude mice have received the most research attention. Furthermore, FAP-targeted NPs have demonstrated superior diagnostic imaging capabilities, even compared to specific methods for each cancer type. Also, they have been safe, with no toxicity. 
Conclusion: FAP-targeted NPs using different ligands, such as Fibroblast Activation Protein Inhibitor (FAPI), can accurately detect tumors and metastases, and outperform specific cancer peptides like PSMA in cancer diagnosis. They are also non-toxic and do not cause radiation damage to tissues. Therefore, FAP-targeted NPs have the potential to serve as a viable alternative to FAP-targeted radionuclides for cancer diagnosis.

تازه های تحقیق

Samaneh Abbasi (PubMed)

Alireza Montazerabadi (Google Scholar)

Amirhossein Sahebkar (Google Scholar)

 

کلیدواژه‌ها
Neoplasms؛ Fibroblast Activation Protein (FAP)؛ Imaging؛ Nanoparticles (NPs)؛ Molecular Imaging
سایر فایل های مرتبط با مقاله
مراجع
  1. Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366-81. doi: 10.1038/s41571-018-0007-1. PubMed PMID: 29651130. PubMed PMCID: PMC5960434.
  2. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582-98. doi: 10.1038/nrc.2016.73. PubMed PMID: 2755820.
  3. Micallef L, Vedrenne N, Billet F, Coulomb B, Darby IA, Desmoulière A. The myofibroblast, multiple origins for major roles in normal and pathological tissue repair. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S5. doi: 10.1186/1755-1536-5-S1-S5. PubMed PMID: 23259712. PubMed PMCID: PMC3368789.
  4. Messerschmidt SK, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release. 2009;137(1):69-77. doi: 10.1016/j.jconrel.2009.03.010. PubMed PMID: 19306900.
  5. Ma J, Dai L, Yu J, Cao H, Bao Y, Hu J, et al. Tumor microenvironment targeting system for glioma treatment via fusion cell membrane coating nanotechnology. 2023;295:122026. doi: 10.1016/j.biomaterials.2023.122026. PubMed PMID: 36731366.
  6. Zhang L, Ying W, Sheng Z, Lv L, Gao J, Xue Y, Liu L. Bioluminescence imaging of fibroblast activation pro-tein-alpha in vivo and human plasma with highly sensitive probe. Anal Biochem. 2022;655:114859. doi: 10.1016/j.ab.2022.114859. PubMed PMID: 35988797.
  7. Zhou S, Zhen Z, Paschall AV, Xue L, Yang X, Bebin-Blackwell AG, et al. FAP-Targeted Photodynamic Therapy Mediated by Ferritin Nanoparticles Elicits an Immune Response against Cancer Cells and Cancer As-sociated Fibroblasts. Adv Funct Mater. 2021;31(7):2007017. doi: 10.1002/adfm.202007017. PubMed PMID: 35822179. PubMed PMCID: PMC9273013.
  8. Borgonje PE, Andrews LM, Herder GJM, de Klerk JMH. Performance and Prospects of [68Ga]Ga-FAPI PET/CT Scans in Lung Cancer. Cancers (Basel). 2022;14(22):5566. doi: 10.3390/cancers14225566. PubMed PMID: 36428657. PubMed PMCID: PMC9688494.
  9. Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48(13):4396-414. doi: 10.1007/s00259-021-05475-0. PubMed PMID: 34173007.
  10. Zhu H, Yang C, Yan A, Qiang W, Ruan R, Ma K, et al. Tumor‐targeted nano‐adjuvants to synergize photo-mediated immunotherapy enhanced antitumor immunity. View. 2023:20220067. doi: 10.1002/VIW.20220067.
  11. Llop J, Lammers T. Nanoparticles for Cancer Diagnosis, Radionuclide Therapy and Theranostics. ACS Nano. 2021;15(11):16974-81. doi: 10.1021/acsnano.1c09139. PubMed PMID: 34748314. PubMed PMCID: PMC7612708.
  12. Xin L, Gao J, Zheng Z, Chen Y, Lv S, Zhao Z, et al. Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review. Front Oncol. 2021;11:648187. doi: 10.3389/fonc.2021.648187. PubMed PMID: 34490078. PubMed PMCID: PMC8416977.
  13. Vallejo-Armenta P, Ferro-Flores G, Santos-Cuevas C, Osvaldo Garcia-Perez F, Casanova-Trivino P, Sandoval-Bonilla B, et al. [99mTc] Tc-iFAP/SPECT tumor stroma imaging: acquisition and analysis of clinical images in six different cancer entities. 2022;15(6):729. doi: 10.3390/ph15060729.
  14. Fan K, Cao C, Pan Y, Lu D, Yang D, Feng J, et al. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol. 2012;7(7):459-64. doi: 10.1038/nnano.2012.90. PubMed PMID: 22706697.
  15. Loomis K, McNeeley K, Bellamkonda RV. Nanoparticles with targeting, triggered release, and imaging func-tionality for cancer applications. Soft Matter. 2011;7(3):839-56. doi: 10.1039/C0SM00534G.
  16. Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Front Oncol. 2021;11:758958. doi: 10.3389/fonc.2021.758958. PubMed PMID: 34858834. PubMed PMCID: PMC8632139.
  17. Koerber SA, Finck R, Dendl K, Uhl M, Lindner T, Kratochwil C, et al. Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(12):3918-24. doi: 10.1007/s00259-021-05374-4. PubMed PMID: 34018010. PubMed PMCID: PMC8484190.
  18. Wei T, Tao W, Cheng Q. Lipid nanoparticles for mRNA therapy: recent advances in targeted delivery. Life Medicine. 2022;1(1):21-3. doi: 10.1093/lifemedi/lnac004.
  19. Li W, Little N, Park J, Foster CA, Chen J, Lu J. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges. Mol Pharm. 2021;18(8):2889-905. doi: 10.1021/acs.molpharmaceut.1c00455. PubMed PMID: 34260250. PubMed PMCID: PMC8752044.
  20. Zhou R, Li M, Wang S, Wu P, Wu L, Hou X. Low-toxic Mn-doped ZnSe@ZnS quantum dots conjugated with nano-hydroxyapatite for cell imaging. Nanoscale. 2014;6(23):14319-25. doi: 10.1039/c4nr04473h. PubMed PMID: 25325899.
  21. Airò Farulla LS, Demirci E, Castellucci P, Alan-Selçuk N, Fortunati E, Gilardi L, Ceci F. Radiolabeled FAP inhibitors as new pantumoral radiopharmaceuticals for PET imaging: a pictorial essay. Clinical and Transla-tional Imaging. 2023;11(1):95-106. doi: 10.1007/s40336-022-00506-8.
  22. Dendl K, Finck R, Giesel FL, Kratochwil C, Lindner T, Mier W, et al. FAP imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies. Eur J Nucl Med Mol Imaging. 2022;49(2):721-31. doi: 10.1007/s00259-021-05488-9. PubMed PMID: 34342669. PubMed PMCID: PMC8803688.
  23. Rüger R, Tansi FL, Rabenhold M, Steiniger F, Kontermann RE, Fahr A, Hilger I. In vivo near-infrared fluo-rescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. J Control Release. 2014;186:1-10. doi: 10.1016/j.jconrel.2014.04.050. PubMed PMID: 24810115.
  24. Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, et al. Positron emission tomography and computed to-mography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in pa-tients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49(4):1322-37. doi: 10.1007/s00259-021-05576-w. PubMed PMID: 34651226.
  25. Coria-Domínguez L, Vallejo-Armenta P, Luna-Gutiérrez M, Ocampo-García B, Gibbens-Bandala B, García-Pérez F, et al. [99mTc]Tc-iFAP Radioligand for SPECT/CT Imaging of the Tumor Microenvironment: Kinetics, Radiation Dosimetry, and Imaging in Patients. Pharmaceuticals (Basel). 2022;15(5):590. doi: 10.3390/ph15050590. PubMed PMID: 35631416. PubMed PMCID: PMC9143259.
  26. McGowan J, Straus S, Moher D, Langlois EV, O’Brien KK, Horsley T, et al. Reporting scoping reviews-PRISMA ScR extension. J Clin Epidemiol. 2020;123:177-9. doi: 10.1016/j.jclinepi.2020.03.016. PubMed PMID: 32229248.
  27. Arksey H, O’malley L. Scoping studies: towards a methodological framework. International Journal of Social Research Methodology. 2005;8(1):19-32. doi: 10.1080/1364557032000119616.
  28. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRIS-MA) statement and publication bias. J Craniomaxillofac Surg. 2011;39(2):91-2. doi: 10.1016/j.jcms.2010.11.001 PubMed PMID: 21145753.
  29. Huang R, Pu Y, Huang S, Yang C, Yang F, Pu Y, Li J, Chen L, Huang Y. FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century. Front Oncol. 2022;12:854658. doi: 10.3389/fonc.2022.854658. PubMed PMID: 35692767. PubMed PMCID: PMC9174525.
  30. Dmochowska N, Milanova V, Mukkamala R, Chow KK, Pham NTH, Srinivasarao M, et al. Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small. 2023;19(21):e2204956. doi: 10.1002/smll.202204956. PubMed PMID: 36840671.
  31. Trujillo-Benítez D, Luna-Gutiérrez M, Ferro-Flores G, Ocampo-García B, Santos-Cuevas C, Bravo-Villegas G, et al. Design, Synthesis and Preclinical Assessment of 99mTc-iFAP for In Vivo Fibroblast Activation Protein (FAP) Imaging. 2022;27(1):264. doi: 10.3390/molecules27010264. PubMed PMID: 35011496. PubMed PMCID: PMC8746441.
  32. Luna-Gutiérrez M, Ocampo-García B, Jiménez-Mancilla N, Ancira-Cortez A, Trujillo-Benítez D, Hernández-Jiménez T, et al. Targeted Endoradiotherapy with Lu2O3-iPSMA/-iFAP Nanoparticles Activated by Neutron Irradiation: Preclinical Evaluation and First Patient Image. Pharmaceutics. 2022;14(4):720. doi: 10.3390/pharmaceutics14040720.
  33. Hernández-Jiménez T, Cruz-Nova P, Ancira-Cortez A, Gibbens-Bandala B, Lara-Almazán N, Ocampo-García B, et al. Toxicity Assessment of [177Lu]Lu-iFAP/iPSMA Nanoparticles Prepared under GMP-Compliant Radiopharmaceutical Processes. Nanomaterials (Basel). 2022;12(23):4181. doi: 10.3390/nano12234181. PubMed PMID: 36500804. PubMed PMCID: PMC9739705.
  34. Yu Q, Qiu Y, Li J, Tang X, Wang X, Cun X, et al. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy. J Control Release. 2020;321:564-75. doi: 10.1016/j.jconrel.2020.02.040. PubMed PMID: 32112854.
  35. Pan Y, Chang T, Marcq G, Liu C, Kiss B, Rouse R, et al. In vivo biodistribution and toxicity of intravesical administration of quantum dots for optical molecular imaging of bladder cancer. Sci Rep. 2017;7(1):9309. doi: 10.1038/s41598-017-08591-w. PubMed PMID: 28839158. PubMed PMCID: PMC5571179.
  36. Caster JM, Yu SK, Patel AN, Newman NJ, Lee ZJ, Warner SB, et al. Effect of particle size on the biodistribu-tion, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy. 2017;13(5):1673-83. doi: 10.1016/j.nano.2017.03.002. PubMed PMID: 28300658. PubMed PMCID: PMC5483200.
  37. Rahman M, Ahmad MZ, Kazmi I, Akhter S, Afzal M, Gupta G, Sinha VR. Emergence of nanomedicine as cancer targeted magic bullets: recent development and need to address the toxicity apprehension. Curr Drug Discov Technol. 2012;9(4):319-29. doi: 10.2174/157016312803305898. PubMed PMID: 22725687.
  38. Dmochowska N, Milanova V, Mukkamala R, Chow KK, Pham NTH, Srinivasarao M, et al. Nanoparticles Targeted to Fibroblast Activation Protein Outperform PSMA for MRI Delineation of Primary Prostate Tumors. Small. 2023;19(21):e2204956. doi: 10.1002/smll.202204956. PubMed PMID: 36840671.
  39. Pandya DN, Sinha A, Yuan H, Mutkus L, Stumpf K, Marini FC, Wadas TJ. Imaging of Fibroblast Activation Protein Alpha Expression in a Preclinical Mouse Model of Glioma Using Positron Emission Tomography. Molecules. 2020;25(16):3672. doi: 10.3390/molecules25163672. PubMed PMID: 32806623. PubMed PMCID: PMC7464128.
  40. Yanagawa N, Sugai M, Shikanai S, Sugimoto R, Osakabe M, Uesugi N, et al. High expression of fibroblast-activating protein is a prognostic marker in non-small cell lung carcinoma. Thorac Cancer. 2022;13(16):2377-84. doi: 10.1111/1759-7714.14579. PubMed PMID: 35818720. PubMed PMCID: PMC9376177.
  41. Chen X, Liu X, Wang L, Zhou W, Zhang Y, Tian Y, et al. Expression of fibroblast activation protein in lung cancer and its correlation with tumor glucose metabolism and histopathology. Eur J Nucl Med Mol Imaging. 2022;49(8):2938-48. doi: 10.1007/s00259-022-05754-4. PubMed PMID: 35254482.
  42. Wang C, Wang H, Yang H, Xu C, Wang Q, Li Z, et al. Targeting cancer-associated fibroblasts with hydroxy-ethyl starch nanomedicine boosts cancer therapy. Nano Research. 2023;16(5):7323-36. doi: 10.1007/s12274-023-5394-7.
  43. Luo Y, Zeng Z, Shan T, Xu X, Chen J, He Y, et al. Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy. 2022;12(8):3610-27. doi: 10.7150/thno.70308. PubMed PMID: 35664057. PubMed PMCID: PMC9131278.
  44. Gao G, Sun X, Liu X, Tang R, Wang M, Zhan W, Zheng J, Liang G. FAP-α-Instructed Coumarin Excimer Formation for High Contrast Fluorescence Imaging of Tumor. Nano Lett. 2022;22(16):6782-6. doi: 10.1021/acs.nanolett.2c02540. PubMed PMID: 35943287.
  45. Xu T, Zhao Y, Ding H, Cai L, Zhou Z, Song Z, Chen Y. [68Ga]Ga-DOTA-FAPI-04 PET/CT imaging in a case of prostate cancer with shoulder arthritis. Eur J Nucl Med Mol Imaging. 2021;48(4):1254-5. doi: 10.1007/s00259-020-05028-x. PubMed PMID: 32901354.
  46. Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a sin-gle-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET/CT versus MRI and [18F]-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2021;48(5):1604-17. doi: 10.1007/s00259-020-05095-0. PubMed PMID: 33179149.
  47. Luo Y, Pan Q, Zhang W, Li F. Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pan-creatic Cancer in 68Ga-FAPI PET/CT. Clin Nucl Med. 2020;45(4):310-1. doi: 10.1097/RLU.0000000000002914. PubMed PMID: 31977474.
  48. Kömek H, Can C, Güzel Y, Oruç Z, Gündoğan C, Yildirim ÖA, et al. 68Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the 18F-FDG PET/CT. Ann Nucl Med. 2021;35(6):744-52. doi: 10.1007/s12149-021-01616-5. PubMed PMID: 33934311.
  49. Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2022;49(2):732-42. doi: 10.1007/s00259-021-05441-w. PubMed PMID: 34297193.
  50. Yang Y, Wang J, Liu W, Deng H, Zhao P, Liao W, et al. 89 Zr and 177 Lu labeling of anti-DR5 monoclonal antibody for colorectal cancer targeting PET-imaging and radiotherapy. Journal of Radioanalytical and Nucle-ar Chemistry. 2021;330:997-1005. doi: 10.1007/s10967-021-07979-3.
  51. Tan Y, Fang Z, Tang Y, Liu K, Zhao H. Clinical advancement of precision theranostics in prostate cancer. Front Oncol. 2023;13:1072510. doi: 10.3389/fonc.2023.1072510. PubMed PMID: 36816956. PubMed PMCID: PMC9932923.
  52. Menon N, Mandelkern M. Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Dig Dis Sci. 2022;67(10):4633-4653. doi: 10.1007/s10620-022-07616-3. PubMed PMID: 35908126.
  53. Vaz SC, Oliveira F, Herrmann K, Veit-Haibach P. Nuclear medicine and molecular imaging advances in the 21st century. Br J Radiol. 2020;93(1110):20200095. doi: 10.1259/bjr.20200095. PubMed PMID: 32401541. PubMed PMCID: PMC10993229.
  54. Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E. Theranostic Advances in Breast Can-cer in Nuclear Medicine. Int J Mol Sci. 2021;22(9):4597. doi: 10.3390/ijms22094597. PubMed PMID: 33925632. PubMed PMCID: PMC8125561.
  55. Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT Us-ing Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2021;62(2):201-7. doi: 10.2967/jnumed.120.245084. PubMed PMID: 32591493. PubMed PMCID: PMC8679591.
  56. Allott L, Aboagye EO. Chemistry Considerations for the Clinical Translation of Oncology PET Radiopharma-ceuticals. Mol Pharm. 2020;17(7):2245-59. doi: 10.1021/acs.molpharmaceut.0c00328. PubMed PMID: 32433888.
  57. Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J Nucl Med. 2021;62(2):201-7. doi: 10.2967/jnumed.120.245084. PubMed PMID: 32591493. PubMed PMCID: PMC8679591.
آمار
تعداد مشاهده مقاله: 571
تعداد دریافت فایل اصل مقاله: 450


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب